1AI
Director Trades
| Date | Director | Value |
|---|
Company News
Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation
Algorae Pharmaceuticals (ASX: 1AI) has reported a period of significant expansion as it broadens its operations to include complementary commercial activities. In the three months to end September, the company advanced its dual-track strategy of AI-driven innovation and pharmaceutical commercialisation, securing two landmark deals to expand its presence across Australia and New Zealand. Algorae also advanced […]
Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership
Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […]
Algorae Pharmaceuticals to Launch Five New Oncology Medicines in Australia-New Zealand Markets
Algorae Pharmaceuticals (ASX: 1AI) has entered into an exclusive licencing agreement with Indian pharmaceutical manufacturer Sakar Healthcare to launch five generic oncology medicines into the Australian and New Zealand markets. The products will be marketed under the Algorae brand to meet the needs of the combined market, which analysts value at approximately $10 million per […]
Algorae Pharmaceuticals Advances Validation for Oncology-Focused Predictive Drug Combinations
Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne’s Peter MacCallum Cancer Centre. The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug […]
Algorae Pharmaceuticals teams with Peter MacCallum Centre to validate AI-predicted cancer drug synergies
Algorae Pharmaceuticals (ASX: 1AI) has partnered with the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre in Melbourne to validate AI-predicted drug synergies using high-throughput screening. The companies will conduct a study to confirm the efficacy of drug combinations and dose ranges across four distinct cancer cell lines including glioblastoma, pancreatic […]
Algorae Pharmaceuticals strengthens drug pipeline as AlgoraeOS Version 2.0 development continues
Algorae Pharmaceuticals (ASX: 1AI) has reported continued advancements to its proprietary Algorae Operating System (or AlgoraeOS) artificial intelligence (AI) drug discovery platform since it was officially launched in September. The AI-driven innovation has identified 24 novel drug targets in the past seven months, focusing on high-impact oncology indications such as breast cancer, leukaemia and glioblastoma. […]
Algorae Pharmaceuticals strengthens leadership team with appointment of new chief commercial officer
Algorae Pharmaceuticals (ASX: 1AI) has strengthened its leadership team with the appointment of seasoned pharmaceutical executive Vishal Shah to the role of chief commercial officer. Mr Shah has over 20 years’ experience in the pharmaceuticals, biotechnology and healthcare industries. He will spearhead Algorae’s commercial strategy to accelerate growth and expansion into complementary pharmaceutical market segments. […]
Algorae Pharmaceuticals to use R&D tax rebate to advance AI-driven drug discovery programs
Algorae Pharmaceuticals (ASX: 1AI) has received a tax rebate of $451,359 from the Australian Taxation Office (ATO) for eligible research and development (R&D) activities conducted during the 2023 and 2024 financial years. The rebate falls under a federally administered tax incentive program available to different industries with the aim of shaping Australia’s economic future and […]
Algorae Pharmaceuticals advances R&D pipeline as AI-driven drug trials continue
Novel treatment development company Algorae Pharmaceuticals (ASX: 1AI) says it is well placed to advance its innovative therapeutic pipeline and artificial intelligence (AI)-driven drug discovery plans. In releasing its quarterly results, the company said it is in a strong financial position with $2.4 million in cash as of 31 December 2024, providing sufficient funding for […]
Weekly wrap: record highs followed by a slight slip
The Australian share market had another positive week, reaching fresh record highs twice before slipping back a little in Friday trade. By the close on Friday the ASX 200 Index was down 0.1% or 8.1 points to 8436.2, as seven of the 11 sectors fell. That followed on from Thursday’s fresh record high of 8444.3 […]